Tuesday, 25 May 2021 05:26

Qorvo Omnia™ SARS-CoV-2 Antigen Test

In April 2021, Qorvo were granted emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Qorvo Omnia™ SARS-CoV-2 Antigen Test. The EUA approval is a major milestone in the collaboration between Qorvo and SCHOTT MINIFAB over the past two years.

FREE WEBINAR - 3 x 20 MINUTE EXPERT SESSIONS
 
Point-of-Care diagnostic consumable development: Don’t underestimate the importance of biochemistry expertise!

It is without question that the global pandemic has created an explosion in the demand for automated point-of-care consumables. In the face of this demand, the race to launch new innovative diagnostics has never been run at a faster pace. 
 
However, significant challenges remain in translating lab-based assays onto automated high-performance consumables. Foremost among these are the challenges presented by the integration and optimization of biochemistries. Indeed, it is probably the single most underestimated step toward successfully developing and commercializing a diagnostic consumable.
 
Through three 15-minute segments followed by a Q&A, this educational webinar addresses best practices in overcoming these development challenges by three thought leaders in this field.
 
Specifically, participants can expect to learn:
  • Fundamental elements of the process for successful assay translation through an early design perspective.
  • A universal workflow for complex microarray development and performance optimization
  • The performance advantages of nanoparticle bioconjugation in point-of-care assay development 
 

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.

Tuesday, 08 December 2020 05:20

SCHOTT MINIFAB - IVD Microfluidics Webinar

What does it take to create a successful microfluidic diagnostic device? Learn from the world leaders in both glass and polymer. 9am CET 18 December 2020. Limited places so register now.

TearLab® Corporation, together with SCHOTT MINIFAB are celebrating an important milestone with the delivery of the 20 millionth microfluidic eye test card from the production line in Melbourne, Australia. The milestone comes as a result of a 13-year contract manufacturing partnership between the two companies, beginning in 2007 with an ambitious microfluidic product development program.

When it comes to managing and mitigating product development risk, there are six guiding principles that are proven to work.

Page 1 of 2